seed
Stage
2
Investors
About
StemSight develops off-the-shelf regenerative cell therapies using iPSC-derived cells combined with biomaterials to treat corneal blindness by accelerating tissue regeneration and improving safety and delivery of cell therapies.
Explore StemSight's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.